Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,063 | 4,072 | 8,297 | 13,100 | 6,285 |
| Receivables | N/A | N/A | N/A | 300 | N/A |
| TOTAL | $1,382 | $4,677 | $8,780 | $13,629 | $7,139 |
| Non-Current Assets | |||||
| PPE Net | 235 | 261 | 287 | 313 | 335 |
| Other Non-Current Assets | 3,713 | 3,798 | 3,881 | 70 | 48 |
| TOTAL | $3,949 | $4,059 | $4,168 | $383 | $383 |
| Total Assets | $5,331 | $8,736 | $12,947 | $14,012 | $7,522 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,610 | 1,450 | 934 | 1,055 | 1,087 |
| Accrued Expenses | 951 | 2,216 | 1,847 | 1,686 | 827 |
| TOTAL | $2,937 | $4,117 | $3,308 | $2,801 | $1,966 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 8,485 | 8,244 | 8,008 | 3,748 | 3,456 |
| TOTAL | $8,489 | $8,249 | $8,013 | $4,136 | $3,863 |
| Total Liabilities | $11,425 | $12,366 | $11,322 | $6,937 | $5,829 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,597 | 1,439 | 1,419 | 1,419 | 1,036 |
| Common Shares | 44 | 43 | 43 | 43 | 31 |
| Retained earnings | -198,641 | -192,679 | -187,343 | -181,133 | -175,410 |
| Other shareholders' equity | 32 | 32 | 32 | 32 | 32 |
| TOTAL | $-6,095 | $-3,630 | $1,626 | $7,075 | $1,693 |
| Total Liabilities And Equity | $5,331 | $8,736 | $12,947 | $14,012 | $7,522 |